Kitov PHARMA Pathway TO SUCCESS
Follow DD, Notes, Work & Progress of Kitov Timeline by Multiple Sources on Internet & Social Media Outlets
8 July 2020
European Patent CM24,
anti-CEACAM1 Antibody
Source: Kitov Pharma Website Click
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody.
July 2020
Pontifax Group & Ran Nussbaum
Source: Chris Randone - Twitter Click
Ran Nussbaum is a managing partner and co-founder of The Pontifax Group. The fund runs more than 50 portfolio companies all around the World.
July 2020
Pontifax Group
Source: Chris Randone - Twitter Click
This fund stood out to me because since 2019, $14.92 Billion has been Invested into Life Science Companies & Pontifax is tied for third with the number of investments across all other firms with 5 investments.
14 May 2020
Present Phase 1 Data on CM-24
Source: Kitov Pharma Website Click
CM24: On May 14, 2020, we announced that the positive results of a previously reported Phase 1 trial of CM24 were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
22 May 2020
U.S. FDA Acceptance to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
Source: Kitov Pharma Website Click
U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical trial of NT219, a novel agent addressing treatment resistance in advanced cancer. The study will evaluate NT219.
20 May 2020
Kitov Announces U.S. Commercial Launch of Consensi™
Source: Kitov Pharma Website Click
Consensi™ is being sold in the U.S. by Burke Therapeutics, the marketing partner of Kitov’s U.S. distributor, Coeptis Pharmaceuticals.
2013 - 2015
cCAM (Merek) = CM-24 (Kitov)
Source: Chris Randone - Twitter Click
cCAM. Ran Nussbaum involvement with cCAM in 2013. cCAM was sold to Merck in 2015 for $95M with shareholders having the ability to receive up to $600+ Million. But then, In 2015 Merck failed w/ cCAM which is now known as...CM-24.
CM-24 acquired by $KTOV in 2019.
Source: Chris Randone - Twitter Click
CM-24 was acquired by $KTOV in 2019.
$MRK failed with cCAM because of a dosage miss which then decided to stop further clinical development of MK-6018 also known as “CM-24”. $KTOV’s powerful drug in Phase 1 with Bristol Myers Squibb. CM-24 was acquired by $KTOV in 2019.
